Final adult height in children with congenital adrenal hyperplasia treated with growth hormone.

What Was Tested

This clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the context of hyperparathyroidism.

Patients with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically reach a final adult height well below their mid-parental target height.

Who Took Part

The abstract describes 27 patients taking part.

The age groups tagged for this paper are children, teenagers and adults, both men and women.

Thirty-four patients with CAH treated with GH participated in this study.

Nineteen males and 15 females who were predicted to be more than 2 SD below their mid-parental target height or more than 2 SD below the population mean received GH until reaching final adult height.

How the Study Was Run

The study was a nonrandomized prospective study.

The study was conducted at two university hospitals in New York City, NY.

In addition to GH, 27 patients (16 males, 11 females) were also treated with an LHRHa.

The mean duration of GH treatment was 5.6 ± 1.8 yr in males and 4.5 ± 1.6 yr in females.

The mean duration of LHRHa therapy was 3.7 ± 1.7 yr for both sexes.

What Was Measured

Topics PubMed links to this paper include Adrenal Hyperplasia, Congenital, Body Height, Gonadotropin-Releasing Hormone, Human Growth Hormone and Patient Selection.

What This Means in Plain Language

This is a clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 27 patients in people with hyperparathyroidism.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 5 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2011 (The Journal of clinical endocrinology and metabolism), a journal based in United States.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, Hyperparathyroidism research.